
CLAIMS

1. A compound of Formula (I):



(I),

or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein:

each R_1 is independently selected from the group consisting of H and halo;

each R_2 is independently selected from the group consisting of H and halo;

R_3 is selected from the group consisting of H, halo, Me, CN, and $P(O)Me_2$;

each R_4 is independently selected from the group consisting of C_1-C_6 alkyl and C_3-C_6 cycloalkyl, wherein any two of R_4 are optionally taken, together with the atoms to which they are attached, to form a C_3-C_6 cycloalkyl;

n and m are each independently 0, 1, 2, 3, or 4;


p is 0, 1, 2, or 3; and

G is H or is selected from the group consisting of C(O)R, C(O)OR, C(O)NR'R, $C(R')_2$-O-C(O)R, $C(R')_2$-O-C(O)OR, and $C(R')_2$-O-C(O)NR'R, wherein

each R is selected from the group consisting of C_1-C_6 alkyl, phenyl, pyridyl, C_3-C_6 cycloalkyl, and a 4-6 membered heterocyclic ring containing one or two heteroatoms selected from the group consisting of N, O and S as ring members, wherein the C_1-C_6 alkyl, phenyl, pyridyl, C_3-C_6 cycloalkyl, and 4-6 membered heterocyclic ring of R are independently optionally substituted with one or two substituents selected from the group consisting of H, halo, CN, OH, NH_2, C_1-C_3 alkyl, phenyl, C_1-C_4 alkoxy, C_1-C_3 haloalkyl, and C_1-C_3 haloalkoxy; and

each R' is independently selected from the group consisting of H and C_1-C_3 alkyl.


2. The compound of claim 1, or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein the compound is of Formula (I-1):



(I-1),

or a pharmaceutically acceptable salt, stereoisomer or solvate thereof.


3. The compound of claim 1, or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein the compound is of Formula (I-2):



(I-2),

or a pharmaceutically acceptable salt, stereoisomer or solvate thereof.

4. The compound of claim 1, or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein the compound is of Formula (I-3):



(I-3),

or a pharmaceutically acceptable salt, stereoisomer or solvate thereof.


5. The compound of one any of claims 1-4, or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein G is H.


6. The compound of one any of claims 1-4, or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein G is selected from the group consisting of C(O)R, C(O)OR, C(O)NR'R, $C(R')_2$-O-C(O)R, $C(R')_2$-O-C(O)OR, and $C(R')_2$-O-C(O)NR'R.

7. The compound of claim 6, or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein G is selected from the group consisting of C(O)R, C(O)OR, $C(R')_2$-O-C(O)R, and $C(R')_2$-O-C(O)OR.

8. The compound of claim 7, or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein G is selected from the group consisting of C(O)R, C(O)OR, CH_2-O-C(O)R, and CH_2-O-C(O)OR, where each R is independently C_1-C_6 alkyl, and the C_1-C_6 alkyl is optionally substituted with one group selected from H, halo, CN, OH, and NH_2.

9. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein G is selected from the group consisting of:





10. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein R_3 is selected from the group consisting of H, F, Cl, Br, Me, CN, and $P(O)Me_2$.

11. The compound of claim 10, or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein R_3 is $P(O)Me_2$.

12. The compound of claim 1, or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein the compound is selected from the group consisting of:

12-(7,8-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-yl)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione (**A-1**),

8-fluoro-6,11-dihydrodibenzo[b,e]selenepin-11-yl)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione (**A-2**),

7-fluoro-6,11-dihydrodibenzo[b,e]selenepin-11-yl)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione (**A-3**),

8,9-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-yl)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione (**A-4**),

10-fluoro-6,11-dihydrodibenzo[b,e]selenepin-11-yl)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione (**A-5**),

6,11-dihydrodibenzo[b,e]selenepin-11-yl)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione (**A-6**),

7,8,10-trifluoro-6,11-dihydrodibenzo[b,e]selenepin-11-yl)-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione (**A-7**),

7,10-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-yl)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione (**A-8**),

9-fluoro-6,11-dihydrodibenzo[b,e]selenepin-11-yl)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione (**A-9**),

(R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-yl)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione (**B-1**),

(R)-12-((S)-8-fluoro-6,11-dihydrodibenzo[b,e]selenepin-11-yl)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione (**B-2**),

(R)-12-((S)-7-fluoro-6,11-dihydrodibenzo[b,e]selenepin-11-yl)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione (**B-3**),

(R)-12-((S)-8,9-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-yl)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione (**B-4**),

(R)-12-((S)-10-fluoro-6,11-dihydrodibenzo[b,e]selenepin-11-yl)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione (**B-5**),

(R)-12-((S)-6,11-dihydrodibenzo[b,e]selenepin-11-yl)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione (**B-6**),

(R)-12-((S)-7,8,10-trifluoro-6,11-dihydrodibenzo[b,e]selenepin-11-yl)-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione (**B-7**),

(R)-12-((S)-7,10-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-yl)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione (**B-8**)

(R)-12-((S)-9-fluoro-6,11-dihydrodibenzo[b,e]selenepin-11-yl)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione (**B-9**),

(((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-yl)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazin-7-yl)oxy)methyl methyl carbonate (**C-1**),

(((R)-12-((S)-8-fluoro-6,11-dihydrodibenzo[b,e]selenepin-11-yl)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazin-7-yl)oxy)methyl methyl carbonate (**C-2**),

(((R)-12-((S)-7-fluoro-6,11-dihydrodibenzo[b,e]selenepin-11-yl)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazin-7-yl)oxy)methyl methyl carbonate (**C-3**),

(((R)-12-((S)-8,9-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-yl)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazin-7-yl)oxy)methyl methyl carbonate (**C-4**),

(((R)-12-((S)-10-fluoro-6,11-dihydrodibenzo[b,e]selenepin-11-yl)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazin-7-yl)oxy)methyl methyl carbonate (**C-5**),

(((R)-12-((S)-6,11-dihydrodibenzo[b,e]selenepin-11-yl)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazin-7-yl)oxy)methyl methyl carbonate (**C-6**),

(((R)-6,8-dioxo-12-((S)-7,8,10-trifluoro-6,11-dihydrodibenzo[b,e]selenepin-11-yl)-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazin-7-yl)oxy)methyl methyl carbonate (**C-7**),

(((R)-12-((S)-7,10-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-yl)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazin-7-yl)oxy)methyl methyl carbonate (**C-8**),

(((R)-12-((S)-9-fluoro-6,11-dihydrodibenzo[b,e]selenepin-11-yl)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazin-7-yl)oxy)methyl methyl carbonate (**C-9**),

(((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-yl)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazin-7-yl)oxy)methyl ethyl carbonate (**D-1**),

1-(((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-yl)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazin-7-yl)oxy)ethyl methyl carbonate (**D-2**),

(((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-yl)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazin-7-yl)oxy)methyl acetate (**D-3**),

(((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-yl)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazin-7-yl)oxy)methyl isopropyl carbonate (**D-4**),

(R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-yl)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazin-7-yl acetate (**D-5**),

(((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-yl)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazin-7-yl)oxy)methyl (2-methoxyethyl) carbonate (**D-6**),

(((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-yl)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazin-7-yl)oxy)methyl L-valinate (**D-7**),

1-(((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-yl)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazin-7-yl)oxy)ethyl L-valinate (**D-8**), and

(((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-yl)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazin-7-yl)oxy)methyl L-leucinate (**D-9**), or a pharmaceutically acceptable salt, stereoisomer or solvate thereof.

13. A pharmaceutical composition comprising a compound of any one of claims 1-12, or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, and one or more pharmaceutically acceptable carriers.

14. Use of a compound of any one of claims 1-12, or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof in the manufacture of a medicament for use in treating influenza.